233 related articles for article (PubMed ID: 1778888)
1. Liposomal amphotericin B in the treatment of visceral leishmaniasis.
Croft SL; Davidson RN; Thornton EA
J Antimicrob Chemother; 1991 Oct; 28 Suppl B():111-8. PubMed ID: 1778888
[TBL] [Abstract][Full Text] [Related]
2. Liposomal amphotericin B in drug-resistant visceral leishmaniasis.
Davidson RN; Croft SL; Scott A; Maini M; Moody AH; Bryceson AD
Lancet; 1991 May; 337(8749):1061-2. PubMed ID: 1673494
[TBL] [Abstract][Full Text] [Related]
3. A comparison of the activities of three amphotericin B lipid formulations against experimental visceral and cutaneous leishmaniasis.
Yardley V; Croft SL
Int J Antimicrob Agents; 2000 Feb; 13(4):243-8. PubMed ID: 10755238
[TBL] [Abstract][Full Text] [Related]
4. Pharmacodynamics and Biodistribution of Single-Dose Liposomal Amphotericin B at Different Stages of Experimental Visceral Leishmaniasis.
Voak AA; Harris A; Qaiser Z; Croft SL; Seifert K
Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28630200
[TBL] [Abstract][Full Text] [Related]
5. Activity of liposomal amphotericin B (AmBisome) against Leishmania infantum and tissue distribution in mice.
Gradoni L; Davidson RN; Orsini S; Betto P; Giambenedetti M
J Drug Target; 1993; 1(4):311-6. PubMed ID: 8069573
[TBL] [Abstract][Full Text] [Related]
6. Comparative activities of the triterpene saponin maesabalide III and liposomal amphotericin B (AmBisome) against Leishmania donovani in hamsters.
Maes L; Germonprez N; Quirijnen L; Van Puyvelde L; Cos P; Vanden Berghe D
Antimicrob Agents Chemother; 2004 Jun; 48(6):2056-60. PubMed ID: 15155199
[TBL] [Abstract][Full Text] [Related]
7. Therapy of visceral leishmaniasis due to Leishmania infantum: experimental assessment of efficacy of AmBisome.
Gangneux JP; Sulahian A; Garin YJ; Farinotti R; Derouin F
Antimicrob Agents Chemother; 1996 May; 40(5):1214-8. PubMed ID: 8723469
[TBL] [Abstract][Full Text] [Related]
8. Antileishmanial efficacy of amphotericin B bearing emulsomes against experimental visceral leishmaniasis.
Gupta S; Dube A; Vyas SP
J Drug Target; 2007 Jul; 15(6):437-44. PubMed ID: 17613662
[TBL] [Abstract][Full Text] [Related]
9. Comparison of three treatment regimens with liposomal amphotericin B (AmBisome) for visceral leishmaniasis in India: a randomized dose-finding study.
Thakur CP; Pandey AK; Sinha GP; Roy S; Behbehani K; Olliaro P
Trans R Soc Trop Med Hyg; 1996; 90(3):319-22. PubMed ID: 8758093
[TBL] [Abstract][Full Text] [Related]
10. Complete cure of experimental visceral leishmaniasis with amphotericin B in stearylamine-bearing cationic liposomes involves down-regulation of IL-10 and favorable T cell responses.
Banerjee A; De M; Ali N
J Immunol; 2008 Jul; 181(2):1386-98. PubMed ID: 18606693
[TBL] [Abstract][Full Text] [Related]
11. Activity of a heat-induced reformulation of amphotericin B deoxycholate (fungizone) against Leishmania donovani.
Petit C; Yardley V; Gaboriau F; Bolard J; Croft SL
Antimicrob Agents Chemother; 1999 Feb; 43(2):390-2. PubMed ID: 9925541
[TBL] [Abstract][Full Text] [Related]
12. Exploitation of lectinized lipo-polymerosome encapsulated Amphotericin B to target macrophages for effective chemotherapy of visceral leishmaniasis.
Gupta PK; Asthana S; Jaiswal AK; Kumar V; Verma AK; Shukla P; Dwivedi P; Dube A; Mishra PR
Bioconjug Chem; 2014 Jun; 25(6):1091-102. PubMed ID: 24842628
[TBL] [Abstract][Full Text] [Related]
13. Amphotericin B inhibits entry of Leishmania donovani into primary macrophages.
Paila YD; Saha B; Chattopadhyay A
Biochem Biophys Res Commun; 2010 Aug; 399(3):429-33. PubMed ID: 20678487
[TBL] [Abstract][Full Text] [Related]
14. Activities of hexadecylphosphocholine (miltefosine), AmBisome, and sodium stibogluconate (Pentostam) against Leishmania donovani in immunodeficient scid mice.
Escobar P; Yardley V; Croft SL
Antimicrob Agents Chemother; 2001 Jun; 45(6):1872-5. PubMed ID: 11353640
[TBL] [Abstract][Full Text] [Related]
15. Antileishmanial activity of nano-amphotericin B deoxycholate.
Manandhar KD; Yadav TP; Prajapati VK; Kumar S; Rai M; Dube A; Srivastava ON; Sundar S
J Antimicrob Chemother; 2008 Aug; 62(2):376-80. PubMed ID: 18453526
[TBL] [Abstract][Full Text] [Related]
16. Short-course treatment of visceral leishmaniasis with liposomal amphotericin B (AmBisome).
Davidson RN; di Martino L; Gradoni L; Giacchino R; Gaeta GB; Pempinello R; Scotti S; Cascio A; Castagnola E; Maisto A; Gramiccia M; di Caprio D; Wilkinson RJ; Bryceson AD
Clin Infect Dis; 1996 Jun; 22(6):938-43. PubMed ID: 8783690
[TBL] [Abstract][Full Text] [Related]
17. Superior chemotherapeutic efficacy of amphotericin B in tuftsin-bearing liposomes against Leishmania donovani infection in hamsters.
Agrawal AK; Agrawal A; Pal A; Guru PY; Gupta CM
J Drug Target; 2002 Feb; 10(1):41-5. PubMed ID: 11996085
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic and immunomodulatory activities of short-course treatment of murine visceral leishmaniasis with KALSOME™10, a new liposomal amphotericin B.
Asad M; Bhattacharya P; Banerjee A; Ali N
BMC Infect Dis; 2015 Apr; 15():188. PubMed ID: 25884796
[TBL] [Abstract][Full Text] [Related]
19. Targeting of liposomal andrographolide to L. donovani-infected macrophages in vivo.
Sinha J; Mukhopadhyay S; Das N; Basu MK
Drug Deliv; 2000; 7(4):209-13. PubMed ID: 11195427
[TBL] [Abstract][Full Text] [Related]
20. Activity of liposomal amphotericin B against experimental cutaneous leishmaniasis.
Yardley V; Croft SL
Antimicrob Agents Chemother; 1997 Apr; 41(4):752-6. PubMed ID: 9087483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
